GSK3B and Alzheimer disease: Recent studies showed that the expression of glycogen synthase kinase-3β (GSK-3β) and β-catenin, two key molecules of the Wnt/β-catenin signaling pathway, were shown to be significantly different in normal mice and AD model mice (Sun et al., 2019; Menet et al., 2020).